Diabetes mellitus comprises a group of disorders characterized by an absolute or relative deficiency of insulin produced by the pancreatic β cells. Dysfunction and stress of the endoplasmic reticulum (ER) are important pathogenic components of both type 1 and type 2 diabetes mellitus, as well as other autoimmune and neurodegenerative diseases. 1 Specifically, mounting evidence now indicates that homeostatic alterations within the ER are directly involved in the β-cell dysfunction and death observed during the development and progression of diabetes mellitus. 2 Targeting the ER, therefore, offers the possibility of a novel therapeutic approach to managing patients with this condition. Two recently published studies have taken a step closer to this goal by establishing a role for ER stress in both autoimmune and heritable diabetes mellitus. 3, 4 The ER is a multitasking subcellular compartment involved in production of secretory proteins, sterol synthesis, calcium storage and regulation of oxidation-reduction reactions. The ER stress res ponse occurs at the cellular level and is designed to help cells survive in the face of an environ mental insult that leads to ER dysfunction. Engin and colleagues examined ER stress responses in two mouse models of auto immune diabetes mellitus and among a group of patients with type 1 diabetes mellitus. 3 The investigators found that dys regulation of the ER stress response occurred during the progression of type 1 diabetes mellitus in both mice and humans. A compound known to counteract ER stress, tauroursodeoxycholic acid (TUDCA), was able to prevent β-cell death in the two mouse models used by Engin and co-workers. This effect of TUDCA was dependent on the activity of ATF6, a critical transcription factor in the ER stress response. In addition, TUDCA did not alter the type and number of immune cells present in the pancreas, but prevented the infiltration of these cells into the islets. These results strongly suggest that maintaining ER homeostasis in pancreatic β cells might prevent lymphocytic infiltration and protect β cells from autoimmune attack, with TUDCA acting like 'molecular armour' for the β cells. Consequently, the interesting possibility is raised that individuals whose pancreatic β cells have 'healthy' ER stress responses could be more resistant to developing type 1 diabetes mellitus than those with dysfunctional β-cell ER responses.
The findings of Engin et al. highlight the importance of identifying bio markers that define ER health; nevertheless, this goal requires the availability of a suitable experimental model. Wolfram syndrome is a rare autosomal recessive disorder that is considered a prototype of human ER disease. 5 Wolfram syndrome is caused by ER dysfunction owing to the loss of function of a transmembrane protein (wolframin; encoded by the WFS1 gene) localized to the ER. Despite its rarity (1 in 200,000-500,000 indivi duals in the general population), Wolfram syndrome probably represents the best model currently available for identifying biomarkers of ER health. Furthermore, this syndrome is characterized by juvenile-onset diabetes mellitus, making it ideal for studying the pathology of β-cell death. 6 Another advantage in using Wolfram syndrome as an experimental model is the fact that it arises from mutation of a single gene (WFS1), a gene shown to be also involved in β-cell dysfunction and death in type 2 diabetes mellitus and a heritable form of adult-onset diabetes mellitus. 7, 8 Its monogenic aetiology makes Wolfram syndrome more amenable to teasing out the mechanisms under pinning cellular responses to ER dysfunction than other diabetic conditions, such as type 1 diabetes mellitus, in which multiple factors typically interact to produce the disease manifestations. Thus, Wolfram syndrome represents an ideal model to shed new light on the underlying causes of diabetes mellitus.
Shang and co-workers took a cell biology approach and successfully generated β cells in vitro using induced pluripotent stem cells (iPSCs) derived from skin cells of patients with Wolfram syndrome. 4 Briefly, iPSCs are artificially derived stem cells that can be induced to differentiate into various types of tissues, including pancreatic β cells and neurons. These 'Wolfram iPSC-derived β cells' were found to have increased levels of ER stress and decreased insulin content. Upon exposure to inducers of β-cell ER stress, Wolfram iPSC-derived β cells showed impaired insulin processing and failed to increase insulin secretion in response to '' ...homeostatic alterations within the ER are directly involved in ... β-cell dysfunction and death...
''
NP G glucose and glucagon-like peptide 1 agonists. Moreover, reduction of ER stress by 4-phenyl butyric acid, a chemical chaperone aiding protein folding in the ER, restored both insulin synthesis and the ability to increase insulin secretion in Wolfram iPSC-derived βcells. The study by Shang et al. validated the roles of WFS1 in insulin production, insulin secretion and protection against ER stress in β cells. 9, 10 The next important step will be to identify biomarkers for ER stress using these cells and to test the efficacy of drugs that might potentially protect β cells from death arising from ER dysfunction.
Taken together, the studies by Polycystic ovary syndrome (PCOS) is a common and very heterogeneous condition characterized by clinical and/or biochemical androgen excess, ovulatory dysfunction and polycystic ovaries (PCO). 1 Over the past few years, many groups have prepared papers on various aspects of PCOS: its diagnostic criteria, its short-term and long-term health consequences and its therapeutic management. 2, 3 However, none of these documents were developed using a validated evidencebased approach. A task force appointed by the Endocrine Society has now developed an evidence-based clini cal practice guideline on the diagnosis and treatment of PCOS using a well-established scientific approach. 3 For the diagnosis of PCOS in adults, the guidelines recommend following the criteria established during the Consensus Con ference held in Rotterdam in 2003, 1 that is, two of the following three cri teria should be met: clinical or biochemical hyperandro genism; ovulatory dysfunction; and PCO. This point is particularly interesting in light of the different conclusion reached by the Androgen Excess and PCOS Society using a similar scientific approach based on a systematic review of the literature (use of hyper androgenism as the main criter ion, plus ovarian dysfunction, defined as o ligoovulation and anovulation, and/or PCO). 2 Another important issue is the need to com pletely evaluate the different features of PCOS. The task force states, "we do not endorse the need for universal screening with androgen assays or ultrasound if patients already meet two of the three criteria clinically". 3 However, an increasing body of evidence demonstrates the extreme variability in short-term and long-term risks in patients with PCOS. 4, 5 The diagnosis of PCOS in adolescent, perimenopausal and postmenopausal women is considered elusive as the specific features of PCOS and their combination as diag nostic criteria have not been validated. Although we are probably very far from a solution to the problem, this topic is very important given that early diagnosis and early intervention (for example, lifestyle modifications) in adolescents could modify the natural history of PCOS.
